Table 2.
Lys65Xaa alterations in hFFA2 have limited effects in assays that are transduced via Gi-G proteins.
| Assay | Agonist | WT | K65R | K65A | K65E |
|---|---|---|---|---|---|
| cAMP | C3 | 3.90 ± 0.09 | 3.42 ± 0.06** | 3.20 ± 0.11*** | 3.79 ± 0.08 |
| Compound 1 | 6.37 ± 0.06 | 6.18 ± 0.08 | 6.54 ± 0.10 | 6.47 ± 0.13 | |
| AZ1729 | 6.35 ± 0.13 | 6.47 ± 0.15 | 6.42 ± 0.03 | 6.45 ± 0.15 | |
| GTPγS | C3 | 3.59 ± 0.08 | 3.29 ± 0.08* | 2.83 ± 0.06*** | 3.21 ± 0.05** |
| Compound 1 | 6.46 ± 0.04 | 6.52 ± 0.06 | 5.68 ± 0.08*** | 5.98 ± 0.07*** | |
| AZ1729 | 6.97 ± 0.02 | 6.79 ± 0.07 | 6.94 ± 0.14 | 6.79 ± 0.12 | |
| Expression (% of WT) | 100 ± 1 | 187 ± 3 | 96 ± 1 | 97 ± 1 | |
Values represent pEC50 of agonists in respective assays. Data are mean ± SEM with n ≥ 3. *p ≤ 0.05. **p ≤ 0.01. ***p ≤ 0.001. One-way analysis of variance was followed by Dunnett’s test with WT as reference.